Accuracy of brain amyloid detection in clinical practice using cerebrospinal fluid β-amyloid 42: a cross-validation study against amyloid positron emission tomography.
about
Attitudes of Research Participants and the General Public Regarding Disclosure of Alzheimer Disease Research ResultsCerebrospinal fluid biomarkers of neurovascular dysfunction in mild dementia and Alzheimer's diseaseCerebrospinal fluid analysis detects cerebral amyloid-β accumulation earlier than positron emission tomographyCerebrospinal Fluid Biomarkers for Alzheimer's Disease: A View of the Regulatory Science Qualification Landscape from the Coalition Against Major Diseases CSF Biomarker TeamDiagnostic Values of Cerebrospinal Fluid T-Tau and Aβ₄₂ using Meso Scale Discovery Assays for Alzheimer's DiseaseThe Gothenburg MCI study: Design and distribution of Alzheimer's disease and subcortical vascular disease diagnoses from baseline to 6-year follow-upAssociation of Amyloid Pathology With Myelin Alteration in Preclinical Alzheimer Disease.Comparison of CSF markers and semi-quantitative amyloid PET in Alzheimer's disease diagnosis and in cognitive impairment prognosis using the ADNI-2 database.Insulin Resistance is Associated with Higher Cerebrospinal Fluid Tau Levels in Asymptomatic APOEɛ4 CarriersDetailed comparison of amyloid PET and CSF biomarkers for identifying early Alzheimer diseaseIndependent information from cerebrospinal fluid amyloid-β and florbetapir imaging in Alzheimer's diseaseCerebrospinal fluid biomarkers and cerebral atrophy in distinct clinical variants of probable Alzheimer's disease.Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis.Effect of Cognitive Reserve on Age-Related Changes in Cerebrospinal Fluid Biomarkers of Alzheimer Disease.Alzheimer's disease cerebrospinal fluid biomarker in cognitively normal subjects.Diagnostic value of cerebrospinal fluid Aβ ratios in preclinical Alzheimer's diseaseUsing florbetapir positron emission tomography to explore cerebrospinal fluid cut points and gray zones in small sample sizes.Cardiorespiratory Fitness Attenuates the Influence of Amyloid on Cognition.Use of amyloid-PET to determine cutpoints for CSF markers: A multicenter study.Alzheimer's Biomarkers are Correlated with Brain Connectivity in Older Adults Differentially during Resting and Task States.Cerebrospinal Fluid Markers of Alzheimer's Disease Pathology and Microglial Activation are Associated with Altered White Matter Microstructure in Asymptomatic Adults at Risk for Alzheimer's Disease.CSF Aβ42/Aβ40 and Aβ42/Aβ38 ratios: better diagnostic markers of Alzheimer disease.Increased amyloidogenic APP processing in APOE ɛ4-negative individuals with cerebral β-amyloidosis.The Vanderbilt Memory & Aging Project: Study Design and Baseline Cohort OverviewCerebrospinal fluid biomarkers in Alzheimer's disease: Diagnostic accuracy and prediction of dementia.Plasma β-amyloid in Alzheimer's disease and vascular disease.Pittsburgh compound B imaging and cerebrospinal fluid amyloid-β in a multicentre European memory clinic study.18F-AV-1451 tau PET imaging correlates strongly with tau neuropathology in MAPT mutation carriers.Insulin Resistance is Associated with Increased Levels of Cerebrospinal Fluid Biomarkers of Alzheimer's Disease and Reduced Memory Function in At-Risk Healthy Middle-Aged Adults.Plasma tau in Alzheimer disease.Cerebrospinal Fluid Levels of Amyloid Beta 1-43 Mirror 1-42 in Relation to Imaging Biomarkers of Alzheimer's Disease.Unbiased estimates of cerebrospinal fluid β-amyloid 1-42 cutoffs in a large memory clinic population.A multinational study distinguishing Alzheimer's and healthy patients using cerebrospinal fluid tau/Aβ42 cutoff with concordance to amyloid positron emission tomography imaging.Cerebrospinal fluid biomarkers in trials for Alzheimer and Parkinson diseases.Can insulin signaling pathways be targeted to transport Aβ out of the brain?Imaging β-amyloid using [(18)F]flutemetamol positron emission tomography: from dosimetry to clinical diagnosis.PET Tau and Amyloid-β Burden in Mild Alzheimer's Disease: Divergent Relationship with Age, Cognition, and Cerebrospinal Fluid BiomarkersA Review of Fluid Biomarkers for Alzheimer's Disease: Moving from CSF to Blood.Cerebrospinal fluid biomarkers in Alzheimer's and Parkinson's diseases-From pathophysiology to clinical practice.The Role of Cerebrospinal Fluid Biomarkers in the Evolution of Diagnostic Criteria in Alzheimer's Disease: Shortcomings in Prodromal Diagnosis.
P2860
Q27345258-A7F428FB-6864-4BA2-B9C9-5ADF17C3F02AQ28087176-85F8F98A-661A-414E-A4AC-2BC071471867Q28273817-519354F1-5A74-4A1D-B0FA-04D6B8A590BCQ28595520-2BEB633D-8711-44D8-B40C-3F0CBBC25CD4Q30659251-60763BB6-79AC-4411-9301-9BE31D9CDBD0Q30980369-208B2173-51BC-4692-86C6-9574D177E552Q31142230-08E63AFA-75D7-474E-A411-04F9CA53E9D3Q33604453-7A74A30D-1F70-4D3B-A685-E68FD16A72D5Q34468797-FD237CDE-C005-48AF-8B31-285641FEAF3BQ34493453-AEAF9762-C14D-48F7-AC5F-F8E0D29E40B9Q35119389-A41CB6A9-E48C-427B-94BA-38466789E4BBQ35735066-AC789487-53FD-4497-AAD6-B2FFAF6B41DBQ35800785-27B39194-7599-4AF9-A849-00FE0ADEB57DQ36265279-C74AD864-D316-4876-9B3C-06BF764A7755Q36276506-A5FB6595-EE98-45C0-9B3B-A07EBE7F7FB3Q36383749-11D0AFD4-609E-4316-B947-07C28BB85A71Q36404504-25F36581-4067-4448-A363-3EAC036B03C2Q36473298-F026EE45-1B2C-4EFB-B231-3FCD5BCD69E5Q36515507-AF992E42-4C8A-445B-BA10-5A11E2A675AFQ36554846-4727AD53-7777-4140-AD26-F1CA0BB58BD8Q36599172-5C218F07-6985-461F-9468-4F99B0E551F7Q36639655-543D3345-5AE3-4153-8892-A7CB322F72E0Q36674545-2E5E975D-19C1-4B42-AAA3-964D73E96709Q36900819-37B10F63-39D4-4BF2-AD0E-D129A8791669Q36933691-F9741CA8-CEE2-43F4-8336-3EEC10DDE1DEQ36949501-2D4CAC1B-7D92-4737-B5C1-F4318757C93BQ37198556-845C63B8-BC54-4159-A545-BB8F7C0E817CQ37198563-214D7818-07A8-435A-808F-5B9F3FA43676Q37343162-795A6B79-CAE4-4126-8C2C-136C8E92CBC8Q37384690-E8120EBC-77A2-4A45-8A11-AC5D4A83EC1CQ37627051-447901A2-A8B8-447E-84E7-67F7C86339A1Q37640765-23484C3E-847E-4F7C-8078-295E4EB0D8ADQ37710439-4B4CEE6B-E998-4AEE-90CA-B24FF0EB9EF6Q38289739-7883AF9F-306B-4E52-BA63-73B3652EBCA6Q38542045-153328C7-312C-4DC4-B2FC-05F93A50E7ECQ38600277-24149DE5-8584-4CA1-BDAA-C210AB5BEF35Q38628805-FFEE73D8-5D03-4BCD-AF4D-22506E50C2A6Q38653401-CE5D176C-9242-4BDF-9244-7F1E0B635DEDQ38825497-8A75B528-889E-4738-91E1-75BD15DD9C9EQ38830945-FA89BD3A-1235-4769-8EDE-0B7D3242FE56
P2860
Accuracy of brain amyloid detection in clinical practice using cerebrospinal fluid β-amyloid 42: a cross-validation study against amyloid positron emission tomography.
description
2014 nî lūn-bûn
@nan
2014 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Accuracy of brain amyloid dete ...... positron emission tomography.
@ast
Accuracy of brain amyloid dete ...... positron emission tomography.
@en
Accuracy of brain amyloid dete ...... positron emission tomography.
@nl
type
label
Accuracy of brain amyloid dete ...... positron emission tomography.
@ast
Accuracy of brain amyloid dete ...... positron emission tomography.
@en
Accuracy of brain amyloid dete ...... positron emission tomography.
@nl
prefLabel
Accuracy of brain amyloid dete ...... positron emission tomography.
@ast
Accuracy of brain amyloid dete ...... positron emission tomography.
@en
Accuracy of brain amyloid dete ...... positron emission tomography.
@nl
P2093
P50
P1433
P1476
Accuracy of brain amyloid dete ...... positron emission tomography.
@en
P2093
David J Brooks
Douglas Hägerström
Per Wollmer
Rikard Owenius
Sebastian Palmqvist
Susanna Vestberg
Ulf Andreasson
P304
P356
10.1001/JAMANEUROL.2014.1358
P407
P577
2014-10-01T00:00:00Z